Assessment of Conservative Combination Therapies for Active and Stable Peyronie’s Disease: A Systematic Review and Meta-analysis

Pyrgidis, Nikolaos; Yafi, Faysal A.; Sokolakis, Ioannis; Dimitriadis, Fotios; Mykoniatis, Ioannis; Russo, Giorgio Ivan; Verze, Paolo; Hatzichristodoulou, Georgios

doi:10.1016/j.euf.2021.12.003

Cited by 15 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 According to published data, PD incidence increases with age and peaks in the fifth decade of age [6][7][8] with a median age at presentation of 54.3 years. 9 However, a not negligible proportion of young men are affected by this condition. 10,11 Previous studies demonstrated that younger men presenting for sexual dysfunction (e.g., ED) have lower sexual satisfaction for the same erectile function status and may deserve more clinical attention, thus requiring an even more tailored management work-up.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The symptomatic burden of Peyronie's disease at presentation according to patient age: A critical analysis of the Peyronie's disease questionnaire (PDQ) domains

et al. 2022

View full text Add to dashboard Cite

Background Peyronie's disease (PD) has a huge impact on patients’ physical and psychological wellbeing. Objectives To investigate whether patients’ age has an impact on PD symptomatic burden at first presentation. Materials and methods Data from 129 consecutive heterosexual patients seeking first medical attention for PD at a single andrological tertiary‐referral centre were collected. All patients completed the International Index for Erectile Function (IIEF) and the PD questionnaire (PDQ). Descriptive statistics were used to compare clinical features between younger (≤40years) and older (>40 years) patients. Multivariable linear model assessed the impact of age, the degree of penile curvature and their impact on PDQ (total scores and its domains), after adjusting for PD duration and IIEF‐erectile function domain scores. Results Of 129, 24 (18.6%) patients were ≤40 years old. Young patients presented with a less severe curvature than older patients (median [interquartile ranges] 20° [15–36] vs. 50° [40–80]; p = 0.04). However, younger age was associated with higher psychological and physical symptoms, PDQ‐penile pain and PDQ‐symptom bother scores (Coeff −0.11, −0.21 and −0.17, respectively) (all p < 0.05). Moreover, the greater the degree of curvature, the higher the PDQ–psychological and physical symptoms and the PDQ‐symptom bother scores (Coeff. 0.21 and 0.22, respectively; all p < 0.05). Conclusion Around one in five men seeking first medical help for PD is younger than 40 years at presentation in the real‐life setting. PD‐related distress varies according to patients’ age, with younger men presenting with a greater risk of penile pain and symptom bother despite lower curvature.

show abstract

Section: Introductionmentioning

confidence: 99%

“…According to published data, PD incidence increases with age and peaks in the fifth decade of age 6–8 with a median age at presentation of 54.3 years 9 . However, a not negligible proportion of young men are affected by this condition 10,11 .…”

Section: Introductionmentioning

confidence: 99%

The symptomatic burden of Peyronie's disease at presentation according to patient age: A critical analysis of the Peyronie's disease questionnaire (PDQ) domains

et al. 2022

View full text Add to dashboard Cite

show abstract

“…108,109 However, a recent meta-analysis investigating 23 combined therapy studies, performed on a total of 1962 participants, failed to show improvement in symptoms of combination therapies compared with monotherapy. 27…”

Section: Combination Therapymentioning

confidence: 99%

Current trends in non‐surgical management of Peyronie's disease—A narrative review

Kozub,

Suleja,

Chłosta

et al. 2023

Andrology

View full text Add to dashboard Cite

Peyronie's disease (PD) is a connective tissue disorder affecting the tunica albuginea. It can cause pain and penile deformation, and its prevalence increases with age. Although surgery is the gold standard for the chronic phase of the disease, there are several conservative treatment methods available, and the optimal management of the acute phase of the disease remains a matter of debate. In this article, we aim to summarize the recent trends in research on the subject of non‐surgical treatment of PD. The search was performed in PubMed, Scopus, and Web of Science databases and included studies in English published between 2012 and 2022 investigating the clinical outcomes of non‐surgical PD management in humans. We have identified 20 distinct conservative treatment strategies. Among the oral therapeutics, only the use of phosphodiesterase type 5 inhibitors is currently recommended for clinical use in patients with concomitant erectile dysfunction. The use of collagenase from Clostridium histolyticum is supported by the best quality evidence in terms of intralesional injections for patients suffering from significant penile curvature; however, interferon alpha‐2b can also be an option in such patients. Among other non‐invasive methods, extracorporeal shockwaves can be useful for pain reduction, and penile traction therapy can lead to a reduction in penile curvature and plaque size. Despite a wide range of non‐surgical methods available for PD treatment, the majority are not supported by sufficient scientific evidence, and the treatment efficacy is underwhelming. Further research on the subject of non‐surgical management of PD is highly warranted.

show abstract

“…Furthermore, PD leads to many complications that may remarkably reduce the quality of life of males ( Milenkovic et al, 2020 ). Due to the lack of understanding of the pathology, there is currently no conservative or medical treatment for PD ( Pyrgidis et al, 2021 ). Therefore, elucidating the underlying pathogenic mechanisms, especially the molecular signaling processes and transcriptional changes, could help develop clinical strategies to treat PD.…”

Section: Introductionmentioning

confidence: 99%

Identifying hub genes, key pathways and key immune-related genes in Peyronie’s disease by integrated bioinformatic analysis

Cui

Chen

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Scarring diseases, such as Peyronie’s disease (PD), usually lead to disorders in the immune system. Previous studies suggested that the PD process was regulated by immune signaling. However, the pathogenetic mechanism remains incompletely characterized. This article used bioinformatic approaches to identify hub genes, key pathways and key immune-related genes that play essential roles in PD pathogenesis. Two Gene Expression Omnibus (GEO) datasets, GSE126005 and GSE146500, were used to analyse the transcriptional profiling in both PD and normal samples. R software was applied to examine the difference in the expression of hub genes and key immune-related genes. The candidates for hub genes were further validated through protein–protein interactions (PPIs), gene correlation, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. In addition, candidate miRNA‒mRNA pairs were functionally assessed. A total of 39 candidate genes were identified, the expression levels of which in PD fibroblast cells were different from those in normal cells (16 showed reduced expression in PD and 21 candidates overexpressed in PD). We found that these genes could interact with each other through PPI analysis. According to the functional enrichment analysis, the candidates may regulate some major biological processes, including cytokine‒cytokine receptor interactions and the JAK-STAT signaling pathway. IL6, IL21R, IFNE, CXCL2, EGF, and ANGPTL5 were identified as key immune-related genes. The findings may help understand the role of immunologic contributors in PD, thus shedding light on the development of more effective strategies to prevent and treat this kind of disease.

show abstract

Assessment of Conservative Combination Therapies for Active and Stable Peyronie’s Disease: A Systematic Review and Meta-analysis

Cited by 15 publications

References 50 publications

The symptomatic burden of Peyronie's disease at presentation according to patient age: A critical analysis of the Peyronie's disease questionnaire (PDQ) domains

The symptomatic burden of Peyronie's disease at presentation according to patient age: A critical analysis of the Peyronie's disease questionnaire (PDQ) domains

Current trends in non‐surgical management of Peyronie's disease—A narrative review

Identifying hub genes, key pathways and key immune-related genes in Peyronie’s disease by integrated bioinformatic analysis

Contact Info

Product

Resources

About